Education
About Us
Working with TipRanks
Follow Us
Race Oncology Ltd. (AU:RAC)
:RAC
RAC Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.92 - AU$1.94
Previous CloseN/A
Volume68.10K
Average Volume (3M)98.58K
Market Cap
AU$205.89M
Enterprise ValueAU$183.63M
Total Cash (Recent Filing)AU$18.78M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Aug 22, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding173,744,380
10 Day Avg. Volume83,063
30 Day Avg. Volume98,581
Financial Highlights & Ratios
PEG Ratio-0.67
Price to Book (P/B)11.05
Price to Sales (P/S)0.00
P/FCF Ratio-250.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Race Oncology Ltd. News
PremiumCompany Announcements
Race Oncology Receives Ethics Approval for Hong Kong Phase 1 Trial
PremiumCompany Announcements
Race Oncology Ltd Announces Quotation of New SecuritiesPremiumCompany Announcements
Race Oncology Ltd Announces Quotation of New Securities
PremiumCompany Announcements
Race Oncology Successfully Doses First Patient in Phase 1 Trial
PremiumCompany Announcements
Race Oncology Ends License Agreement with City of Hope
PremiumCompany Announcements
Race Oncology Ltd Announces Quotation of New Securities on ASX
PremiumCompany Announcements
Race Oncology Announces Cessation of SecuritiesOptions Prices
Currently, No data available
---
Ownership Overview
0.27% Insiders
―
Mutual Funds
― Other Institutional Investors
99.73% Public Companies and
Individual Investors
RAC FAQ
What was Race Oncology Ltd.’s price range in the past 12 months?
Race Oncology Ltd. lowest share price was AU$0.92 and its highest was AU$1.94 in the past 12 months.
What is Race Oncology Ltd.’s market cap?
Race Oncology Ltd.’s market cap is AU$205.89M.
When is Race Oncology Ltd.’s upcoming earnings report date?
Race Oncology Ltd.’s upcoming earnings report date is Aug 22, 2025 which is in 34 days.
How were Race Oncology Ltd.’s earnings last quarter?
Currently, no data Available
Is Race Oncology Ltd. overvalued?
According to Wall Street analysts Race Oncology Ltd.’s price is currently Overvalued.
Does Race Oncology Ltd. pay dividends?
Race Oncology Ltd. does not currently pay dividends.
What is Race Oncology Ltd.’s EPS estimate?
Race Oncology Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Race Oncology Ltd. have?
Race Oncology Ltd. has 173,744,380 shares outstanding.
What happened to Race Oncology Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Race Oncology Ltd.?
Currently, no hedge funds are holding shares in AU:RAC
Race Oncology Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:RAC Sentiment 70%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.29%
12-Months-Change
Fundamentals
Return on Equity
-37.20%
Trailing 12-Months
Asset Growth
2.86%
Trailing 12-Months
Company Description
Race Oncology Ltd.
Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene; and strategic collaboration with the University of Wollongong to evaluate Zantrene formulations. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.
Technical Analysis
Opthea
―
Telix Pharmaceuticals
―
Prescient Therapeutics Limited
―
Biotron
―
Imugene
―